Archives

by in
Entry Author Date Location
Biotech and Fantasy Football Picks for Fall 2013 09/03/13 National
Adimab Turns Cash Flow Positive With GSK, Biogen Tech Transfer Deals 07/26/13 Boston
Vertex Sees Liver Toxicity With Emerging Hep C Drug, Faces FDA Hold 07/25/13 Boston
The Biotech IPO Phenomenon of 2013: Enjoy It While It Lasts 07/22/13 National
Sangamo in Race to Replace Chronic Drug Treatment with Gene Therapies 07/15/13 San Francisco
Why I Won’t Cheer If Onyx Pharma Is Sold for Megabucks 07/15/13 National
Profiles in Long-Termism: Sarepta Therapeutics CEO Chris Garabedian 06/10/13 National
ASCO Wrap-Up: Cancer News from the East, South, & Rockies 06/05/13 National
ASCO Wrap-Up: Cancer News from the West Coast 06/04/13 National
Cardeas Pharma Snags $34M For Antibiotic Against Hospital Infections 05/22/13 Seattle
Savara Enters the Proving Ground With Inhalable Antibiotic for CF 05/01/13 Texas
Gilead Sciences Building on HIV, Becoming Cancer Drug Force 04/01/13 National
East Coast Life Sciences Roundup: GSK, Protein Sciences, IMS Health 03/15/13 Boston
Pfizer Yields to Rivals in Hep C Drug Race 03/13/13 New York
Someone Needs to Rank U.S. Biotech Hubs, For Real 03/04/13 National
Adimab Grows Up, Looks to Pay Off the VCs In Unusual Way 02/22/13 Boston
Infinity Pharmaceuticals Bounces Back To Compete in Crowded Field 02/08/13 Boston
East Coast Life Sciences Roundup: Bristol-Myers, Alnylam, Merck, & More 11/16/12 Boston
Hepatitis C Treatments from Gilead, Abbott Wow Liver Meeting 11/13/12 Boston
East Coast Life Sciences Roundup: Vertex, Thermedical, More 11/02/12 Boston
Betting on Biotech to Catalyze U.S. Job Growth? Don’t Count On It 10/01/12 National
Who’s on Biotech’s Endangered Species List? Mid-Sized Drugmakers 05/21/12 National
SD Life Sciences Roundup: Gen-Probe, Zogenix, & the Innovation Economy 05/03/12 San Diego
Cardeas Gears Up for Clinic, With Drug Combo for Hospital Infections 04/26/12 Seattle
Dyax, Adimab, Mersana, & More Boston Life Sciences Newsmakers 04/20/12 Boston
Some Tongue-in-Cheek Fantasy Baseball (and Biotech) Picks 03/26/12 National
Vertex Stays in HepC Game, as All-Oral Combo Passes Small Study 02/23/12 Boston
Enanta Enters HepC Big Leagues, With $34M Upfront From Novartis 02/21/12 Boston
Vertex Vows to Fight On With Alios Drugs in High-Stakes Hepatitis C Race 01/24/12 Boston
Frazier Healthcare Aims for First Biotech VC Fund After Financial Crisis 01/19/12 Seattle
Page 3 of 7 « previous page · next page »